MIMS Summary: NICE approves Acomplia

NICE has issued final guidance on the use of rimonabant (Acomplia) for the treatment of obesity.

Rimonabant is recommended as an adjunct to diet and exercise in adults who are obese (BMI >30kg/m2) or overweight (BMI >27kg/m) and who have had an inadequate response to, are intolerant of or are contraindicated to orlistat and sibutramine.

The guidance also recommends the following:

  • Treatment with rimonabant should continue beyond 6 months only if the patient has lost at least 5% of their body weight since starting treatment.
  • Treatment should be discontinued if a patient returns to their original weight while on rimonabant.
  • Treatment should not be continued beyond 2 years without a formal clinical assessment and discussion of the risks and benefits with the patient.

Read the full NICE guideline

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Follow Us: